O	0	7	Effects
O	8	10	of
O	11	12	a
B-intervention	13	17	High
O	18	20	vs
B-control	21	29	Moderate
I-control	30	36	Volume
I-control	37	39	of
I-control	40	47	Aerobic
I-control	48	56	Exercise
O	57	59	on
O	60	69	Adiposity
O	70	78	Outcomes
O	79	81	in
O	82	96	Postmenopausal
O	97	102	Women
O	102	103	:
O	104	105	A
O	106	116	Randomized
O	117	125	Clinical
O	126	131	Trial
O	131	132	.

O	133	137	Body
O	138	141	fat
O	142	151	increases
O	152	166	postmenopausal
O	167	173	breast
O	174	180	cancer
O	181	185	risk
O	185	186	.

O	187	195	Physical
O	196	204	activity
O	205	208	may
O	209	217	decrease
O	218	222	risk
O	223	230	through
O	231	240	adiposity
O	241	248	changes
O	248	249	,
O	250	253	but
O	254	257	the
O	258	265	optimal
O	266	270	dose
O	271	273	of
O	274	282	activity
O	283	285	is
O	286	293	unknown
O	293	294	.

O	295	297	To
O	298	305	compare
O	306	309	the
O	310	317	effects
O	318	320	of
O	321	324	300
O	325	327	vs
O	328	331	150
O	332	335	min
O	335	336	/
O	336	338	wk
O	339	341	of
O	342	350	moderate
O	351	353	to
O	354	362	vigorous
O	363	370	aerobic
O	371	379	exercise
O	380	382	on
O	383	387	body
O	388	391	fat
O	392	394	in
O	395	409	postmenopausal
O	410	415	women
O	415	416	.

O	417	420	The
O	421	427	Breast
O	428	434	Cancer
O	435	438	and
O	439	447	Exercise
O	448	453	Trial
O	454	456	in
O	457	464	Alberta
O	465	468	was
O	469	470	a
O	471	473	12
O	473	474	-
O	474	479	month
O	479	480	,
O	481	482	2
O	482	483	-
O	483	488	armed
O	488	489	,
O	490	491	2
O	491	492	-
O	492	498	center
O	499	509	randomized
O	510	514	dose
O	514	515	-
O	515	525	comparison
O	526	531	trial
O	532	541	conducted
O	542	546	from
O	547	551	June
O	552	556	2010
O	557	564	through
O	565	569	June
O	570	574	2013
O	574	575	.

O	576	588	Participants
O	589	593	were
B-total-participants	594	597	400
B-eligibility	598	606	inactive
I-eligibility	607	621	postmenopausal
I-eligibility	622	627	women
I-eligibility	628	632	with
I-eligibility	633	637	body
I-eligibility	638	642	mass
I-eligibility	643	648	index
I-eligibility	649	651	22
I-eligibility	652	654	to
I-eligibility	655	657	40
I-eligibility	657	658	,
I-eligibility	659	666	disease
I-eligibility	666	667	-
I-eligibility	667	671	free
I-eligibility	671	672	,
I-eligibility	673	683	nonsmokers
I-eligibility	683	684	,
I-eligibility	685	688	and
I-eligibility	689	697	nonusers
I-eligibility	698	700	of
I-eligibility	701	710	exogenous
I-eligibility	711	719	hormones
O	719	720	.

O	721	725	Five
O	726	727	d
O	727	728	/
O	728	730	wk
O	731	733	of
O	734	741	aerobic
O	742	750	exercise
O	751	752	(
O	752	753	3
O	754	755	d
O	755	756	/
O	756	758	wk
O	759	769	supervised
O	769	770	,
O	771	772	2
O	773	774	d
O	774	775	/
O	775	777	wk
O	778	790	unsupervised
O	790	791	)
O	792	795	for
O	796	798	30
O	799	802	min
O	802	803	/
O	803	810	session
O	811	812	(
O	812	820	moderate
O	820	821	-
O	821	827	volume
O	827	828	)
O	829	831	or
O	832	834	60
O	835	838	min
O	838	839	/
O	839	846	session
O	847	848	(
O	848	852	high
O	853	859	volume
O	859	860	)
O	861	870	achieving
O	871	873	65
O	873	874	%
O	875	877	to
O	878	880	75
O	880	881	%
O	882	884	of
O	885	890	heart
O	891	895	rate
O	896	903	reserve
O	904	907	for
O	908	910	at
O	911	916	least
O	917	919	50
O	919	920	%
O	921	923	of
O	924	928	each
O	929	936	session
O	936	937	.

O	938	950	Participants
O	951	955	were
O	956	961	asked
O	962	965	not
O	966	968	to
O	969	975	change
O	976	981	usual
O	982	986	diet
O	986	987	.

O	988	993	Total
O	994	998	body
O	999	1002	fat
O	1002	1003	,
O	1004	1012	measured
O	1013	1017	from
O	1018	1022	dual
O	1023	1029	energy
O	1030	1031	x
O	1031	1032	-
O	1032	1035	ray
O	1036	1050	absorptiometry
O	1051	1056	scans
O	1056	1057	,
O	1058	1061	was
O	1062	1065	the
O	1066	1073	primary
O	1074	1081	outcome
O	1081	1082	.

O	1083	1088	Other
O	1089	1097	measures
O	1098	1106	included
O	1107	1119	subcutaneous
O	1120	1123	and
O	1124	1129	intra
O	1129	1130	-
O	1130	1139	abdominal
O	1140	1143	fat
O	1144	1148	from
O	1149	1157	computed
O	1158	1168	tomography
O	1169	1174	scans
O	1174	1175	,
O	1176	1182	weight
O	1182	1183	,
O	1184	1187	and
O	1188	1193	waist
O	1194	1197	and
O	1198	1201	hip
O	1202	1216	circumferences
O	1216	1217	.

O	1218	1220	Of
B-total-participants	1221	1224	400
O	1225	1230	women
O	1230	1231	,
B-total-participants	1232	1235	384
O	1236	1244	provided
O	1245	1253	baseline
O	1254	1257	and
O	1258	1264	follow
O	1264	1265	-
O	1265	1267	up
O	1268	1277	adiposity
O	1278	1290	measurements
O	1290	1291	.

O	1292	1298	Median
O	1299	1300	(
O	1300	1313	interquartile
O	1314	1319	range
O	1319	1320	)
B-outcome	1321	1330	adherence
I-outcome	1331	1333	at
I-outcome	1334	1338	full
I-outcome	1339	1351	prescription
O	1352	1355	for
O	1356	1359	the
O	1360	1364	high
O	1364	1365	-
O	1366	1369	and
O	1370	1378	moderate
O	1378	1379	-
O	1379	1385	volume
O	1386	1392	groups
O	1393	1396	was
B-iv-cont-median	1397	1400	254
O	1401	1402	(
O	1402	1405	166
O	1405	1406	-
O	1406	1409	290
O	1409	1410	)
O	1411	1414	and
B-cv-cont-median	1415	1418	137
O	1419	1420	(
O	1420	1423	111
O	1423	1424	-
O	1424	1427	150
O	1427	1428	)
O	1429	1432	min
O	1432	1433	/
O	1433	1435	wk
O	1435	1436	,
O	1437	1449	respectively
O	1449	1450	.

O	1451	1455	Mean
O	1456	1466	reductions
O	1467	1469	in
B-outcome	1470	1475	total
I-outcome	1476	1479	fat
O	1480	1484	were
O	1485	1498	significantly
O	1499	1505	larger
O	1506	1508	in
O	1509	1512	the
O	1513	1517	high
O	1517	1518	-
O	1519	1521	vs
O	1522	1530	moderate
O	1530	1531	-
O	1531	1537	volume
O	1538	1543	group
O	1544	1545	(
O	1545	1550	least
O	1550	1551	-
O	1551	1558	squares
O	1559	1563	mean
O	1564	1574	difference
O	1574	1575	,
O	1576	1577	-
O	1577	1578	1
O	1578	1579	.
O	1579	1580	0
O	1580	1581	%
O	1582	1583	[
O	1583	1585	95
O	1585	1586	%
O	1587	1589	CI
O	1589	1590	,
O	1591	1592	-
O	1592	1593	1
O	1593	1594	.
O	1594	1595	6
O	1595	1596	%
O	1597	1599	to
O	1600	1601	-
O	1601	1602	0
O	1602	1603	.
O	1603	1604	4
O	1604	1605	%
O	1605	1606	]
O	1606	1607	,
O	1608	1609	P
O	1610	1611	=
O	1612	1613	.
O	1613	1616	002
O	1616	1617	)
O	1617	1618	.

B-outcome	1619	1631	Subcutaneous
I-outcome	1632	1641	abdominal
I-outcome	1642	1645	fat
I-outcome	1646	1649	and
I-outcome	1650	1655	waist
I-outcome	1656	1658	to
I-outcome	1659	1662	hip
I-outcome	1663	1668	ratio
O	1669	1678	decreased
O	1679	1692	significantly
O	1693	1697	more
O	1698	1700	in
O	1701	1704	the
O	1705	1709	high
O	1709	1710	-
O	1710	1716	volume
O	1717	1722	group
O	1723	1724	(
O	1724	1729	least
O	1729	1730	-
O	1730	1737	squares
O	1738	1742	mean
O	1743	1753	difference
O	1753	1754	,
O	1755	1756	-
O	1756	1758	10
O	1758	1759	.
O	1759	1760	8
O	1761	1762	[
O	1762	1764	95
O	1764	1765	%
O	1766	1768	CI
O	1768	1769	,
O	1770	1771	-
O	1771	1773	19
O	1773	1774	.
O	1774	1775	5
O	1776	1778	to
O	1779	1780	-
O	1780	1781	2
O	1781	1782	.
O	1782	1783	2
O	1783	1784	]
O	1785	1787	cm
O	1787	1788	²
O	1788	1789	,
O	1790	1791	P
O	1792	1793	=
O	1794	1795	.
O	1795	1797	01
O	1797	1798	,
O	1799	1802	and
O	1803	1804	-
O	1804	1805	0
O	1805	1806	.
O	1806	1808	01
O	1809	1810	[
O	1810	1812	95
O	1812	1813	%
O	1814	1816	CI
O	1816	1817	,
O	1818	1819	-
O	1819	1820	0
O	1820	1821	.
O	1821	1823	02
O	1824	1826	to
O	1827	1828	0
O	1828	1829	.
O	1829	1831	00
O	1831	1832	]
O	1832	1833	,
O	1834	1835	P
O	1836	1837	=
O	1838	1839	.
O	1839	1841	04
O	1841	1842	,
O	1843	1855	respectively
O	1855	1856	)
O	1856	1857	.

B-outcome	1858	1865	Changes
I-outcome	1866	1868	in
I-outcome	1869	1875	weight
I-outcome	1876	1879	and
I-outcome	1880	1885	intra
I-outcome	1885	1886	-
I-outcome	1886	1895	abdominal
I-outcome	1896	1899	fat
O	1900	1904	were
O	1905	1908	not
O	1909	1922	significantly
O	1923	1932	different
O	1933	1940	between
O	1941	1947	groups
O	1948	1949	(
O	1949	1954	least
O	1954	1955	-
O	1955	1962	squares
O	1963	1967	mean
O	1968	1978	difference
O	1978	1979	,
O	1980	1981	-
O	1981	1982	0
O	1982	1983	.
O	1983	1984	7
O	1985	1986	[
O	1986	1988	95
O	1988	1989	%
O	1990	1992	CI
O	1992	1993	,
O	1994	1995	-
O	1995	1996	1
O	1996	1997	.
O	1997	1998	6
O	1999	2001	to
O	2002	2003	0
O	2003	2004	.
O	2004	2005	2
O	2005	2006	]
O	2007	2009	kg
O	2009	2010	,
O	2011	2012	P
O	2013	2014	=
O	2015	2016	.
O	2016	2018	11
O	2018	2019	,
O	2020	2023	and
O	2024	2025	-
O	2025	2026	1
O	2026	2027	.
O	2027	2028	5
O	2029	2030	[
O	2030	2032	95
O	2032	2033	%
O	2034	2036	CI
O	2036	2037	,
O	2038	2039	-
O	2039	2040	5
O	2040	2041	.
O	2041	2042	9
O	2043	2045	to
O	2046	2047	2
O	2047	2048	.
O	2048	2049	9
O	2049	2050	]
O	2051	2053	cm
O	2053	2054	²
O	2054	2055	,
O	2056	2057	P
O	2058	2059	=
O	2060	2061	.
O	2061	2063	50
O	2063	2064	,
O	2065	2077	respectively
O	2077	2078	)
O	2078	2079	.

O	2080	2084	Some
O	2085	2089	dose
O	2089	2090	-
O	2090	2098	response
O	2099	2106	effects
O	2107	2111	were
O	2112	2120	stronger
O	2121	2124	for
O	2125	2130	obese
O	2131	2136	women
O	2136	2137	.

O	2138	2140	In
O	2141	2151	previously
O	2152	2160	inactive
O	2161	2175	postmenopausal
O	2176	2181	women
O	2181	2182	,
O	2183	2184	a
O	2185	2186	1
O	2186	2187	-
O	2187	2191	year
O	2192	2204	prescription
O	2205	2207	of
O	2208	2216	moderate
O	2217	2219	to
O	2220	2228	vigorous
O	2229	2237	exercise
O	2238	2241	for
O	2242	2245	300
O	2246	2249	min
O	2249	2250	/
O	2250	2252	wk
O	2253	2256	was
O	2257	2265	superior
O	2266	2268	to
O	2269	2272	150
O	2273	2276	min
O	2276	2277	/
O	2277	2279	wk
O	2280	2283	for
O	2284	2292	reducing
O	2293	2298	total
O	2299	2302	fat
O	2303	2306	and
O	2307	2312	other
O	2313	2322	adiposity
O	2323	2331	measures
O	2331	2332	,
O	2333	2343	especially
O	2344	2346	in
O	2347	2352	obese
O	2353	2358	women
O	2358	2359	.

O	2360	2365	These
O	2366	2373	results
O	2374	2381	suggest
O	2382	2392	additional
O	2393	2400	benefit
O	2401	2403	of
O	2404	2410	higher
O	2410	2411	-
O	2411	2417	volume
O	2418	2425	aerobic
O	2426	2434	exercise
O	2435	2438	for
O	2439	2448	adiposity
O	2449	2457	outcomes
O	2458	2461	and
O	2462	2470	possibly
O	2471	2472	a
O	2473	2478	lower
O	2479	2483	risk
O	2484	2486	of
O	2487	2501	postmenopausal
O	2502	2508	breast
O	2509	2515	cancer
O	2515	2516	.
O	2517	2531	clinicaltrials
O	2531	2532	.
O	2532	2535	gov
O	2535	2536	:
O	2537	2548	NCT01435005
O	2548	2549	.
